P&G Throws Weight Behind Consumer Growth After Shedding Pharma
This article was originally published in The Rose Sheet
Executive Summary
Procter & Gamble washes its hands of prescription pharmaceuticals to focus on its consumer brands, though experts say the firm faces obstacles to growing its beauty and OTC portfolio
You may also be interested in...
Alberto-Culver's Noxzema Quality Issues Traced To P&G Facility; Suit Filed
A lawsuit filed by Alberto-Culver against Procter & Gamble - over the Noxzema brand each has parented - bears further testimony to quality control issues at P&G's manufacturing plant in Puerto Rico, which drew an FDA warning letter in April
Procter & Gamble Aims To Recover Growth After Tough 2009
Procter & Gamble is regrouping with revised growth strategies after a tough fiscal 2009 fourth quarter in which sales fell 11 percent to $18.7 billion
P&G Beauty Hungry For Market Share, Aims To Grow On Trade-Up, Regimen Use
Procter & Gamble's campaign to turn consumers onto a wider selection of products under its Gillette umbrella is part of a greater initiative to drive growth of its entire beauty category, P&G Vice-Chairman, Global Beauty and Cosmetics Ed Shirley said